Why small medtechs are exiting Europe — and what we can actually do about it

I started digging into why a handful of colleagues and suppliers are pulling low-margin devices out of Europe because we were facing the same pressure: regulatory cost per product was becoming larger than the product’s contribution to the business. As someone who spends my days mapping traceability and cost-to-compliance for Class II devices, the mechanics behind these exits look familiar — and fixable in some cases, fatal in others.

Where the cost actually comes from

From my practical experience, the pressure isn’t a single headline item. It’s the accumulation of many regulatory and QMS demands that used to be occasional and are now continuous:

• Notified body scrutiny and fees: more detailed assessments, longer review cycles, and higher audit scope lead to increased cost-per-device.
• Clinical evidence and CER/PMCF: updating clinical evaluations and running post-market clinical follow-up (PMCF) when real-world complaints grow is expensive.
• Enhanced post-market surveillance and vigilance: tighter reporting timelines and deeper investigations increase operational costs and documentation overhead.
• Technical documentation and translations: maintaining a full Technical File (or STED) for each variant, plus translation/localization for multiple EU languages, eats time and budget.
• UDI, EUDAMED readiness, and economic operator obligations: UDI assignment, registration, and coordination with authorized representatives or importers add compliance steps.
• QMS upgrades and standards alignment: implementing or enhancing processes to meet ISO 13485:2016 and ISO 14971:2019 expectations, and embedding them across the supply chain.

None of these on their own is insurmountable. The problem is they compound for low-margin consumables, simple disposables, or small accessory lines where the revenue per SKU is tiny but the regulatory attention is the same as a higher-risk device.

Business realities I’ve seen

At my company we ran a routine portfolio review for EU distribution. We calculated “cost to keep on market” rather than “cost to launch,” including annual surveillance fees, required CER refresh cadence, translation costs, and notified body re-assessment scenarios. Two product lines barely covered distribution costs once these regulatory items were loaded in.

Other practical constraints I've observed:

• Distributors prefer one-stop product sets. They balk at carrying items that require individual regulatory hand-holding.
• Smaller manufacturers struggle to amortize clinical evidence across SKUs. Every small variant becomes a disproportionate regulatory burden.
• Consolidation happens fast: some businesses choose to concentrate on a few higher-margin lines and sunset the rest.

What helped in the cases that survived

A few mitigation strategies actually moved the needle when we evaluated them:

• Rationalize SKUs early: fewer variants means fewer technical files, fewer translation files, and simpler post-market surveillance.
• Re-evaluate intended use and classification: in some cases, combining a variant into an existing higher-volume technical file (without changing intended purpose) reduced duplicate work. Be careful: classification and intended use changes must be defensible.
• Centralize clinical evidence: build a clinical evidence strategy that supports a family of devices rather than per-SKU CERs where appropriate.
• Shift to distributor-led regulatory responsibility only when contracts and capabilities allow: where the distributor can lawfully carry more responsibility (and is willing), this reduces your operating overhead.
• Automate evidence management: invest in a QMS tooling approach that helps you reuse artifacts (test reports, risk analyses, trace matrices) across files.

These aren’t magic — they require upfront work and judicious risk management. For some companies the investment to rationalize and automate exceeds what the product will ever return.

When exit is the rational choice

There are times when sunset makes sense:

• The device has very low margins and limited lifecycle — e.g., commodity disposables sold on price alone.
• The commercial model relies on low-touch distribution channels that cannot absorb regulatory complexity.
• Clinical/market feedback doesn’t justify the ongoing PMCF or vigilance investment.

When we recommended exit decisions, we paired them with controlled withdrawal plans: stop new sales in targeted member states, fulfill existing contracts, notify distributors and competent authorities as required, and keep required records so the device could be re-introduced if business conditions change.

What I’d like to see change (policy and tooling)

• More proportionality: regulatory reviewers and notified bodies could apply more proportional evidence expectations for genuinely low-risk, low-impact devices.
• Better tooling for reuse of evidence across device families: standard templates and clearer guidance that supports legitimate reuse of clinical and risk artifacts.
• Clearer expectations around variant management: harmonised guidance on when variants require full separate documentation vs. a simple addendum.

My practical question for you

Has anyone here built a playbook to keep low-margin devices on the EU market without blowing the P&L? What levers worked — SKU rationalization, contract shifts to distributors, tooling investments, or regulatory arguments to reduce evidence scope? I’m especially curious about examples where the economics turned from “sunset” back to “sustain.”